다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Der internist, v.62 no.6, 2021년, pp.605 - 610
Zhou, X. (Medizinische Klinik und Poliklinik II, Universitä) , Einsele, H. (tsklinikum Wü) , Danhof, S. (rzburg, Oberdü)
AI-Helper
Chimeric antigen receptor (CAR) T-cell treatment is a novel immunotherapy utilizing the patientʼs own immune system as a “weapon against tumor cells”. In patients with multiple myeloma (MM), CAR T-cell therapy has been investigated in clinical trials. The current data on B‑c...
Die Behandlung mit CAR-T-Zellen (CAR chimärer Antigenrezeptor) ist eine neuartige Strategie der zellulären Immuntherapie, die das patienteneigene Immunsystem als „Waffe gegen Tumorzellen“ benutzt. Bei Patienten mit multiplem Myelom werden CAR-T-Zell-Therapien im Rahmen klinischer Studien getestet. Die aktuellen Studiendaten der gegen das „B-cell maturation antigen“ (BCMA) gerichteten CAR-T-Zell-Therapien zeigen eine beachtliche Wirksamkeit, die eine baldige Zulassung erwarten lässt. Allerdings erleiden weiterhin die meisten Patienten nach einer Behandlung mit CAR-T-Zellen ein Rezidiv. Hinzu kommt, dass CAR-T-Zell-Therapien zu schwerwiegenden Nebenwirkungen wie Zytokinfreisetzungssyndrom und Neurotoxizität mit teilweise auch letalem Ausgang führen können. Ein angemessenes Kosten-Nutzen-Verhältnis der CAR-T-Zell-Therapie stellt eine weitere Herausforderung dar. Trotz dieser Limitationen erscheint die CAR-T-Zell-Therapie eine attraktive Option für Patienten mit Myelom, sodass diese Therapie das Potenzial hat, in die Standardbehandlung integriert zu werden.
1. Moreau P Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a？randomised, open-label, phase 3？study Lancet 2019 394 10192 29 38 10.1016/S0140-6736(19)31240-1 31171419
2. Voorhees PM Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Blood 2020 136 8 936 945 10.1182/blood.2020005288 32325490
3. Palumbo A Revised international staging system for multiple myeloma: a report from international myeloma working group J Clin Oncol 2015 33 26 2863 2869 10.1200/JCO.2015.61.2267 26240224
4. Usmani SZ Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents Haematologica 2012 97 11 1761 1767 10.3324/haematol.2012.065698 22689675
5. Shah V Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients Leukemia 2020 34 11 3091 3096 10.1038/s41375-020-0750-z 32157174
6. Sun C Safety and efficacy of targeting CD138 with a？chimeric antigen receptor for the treatment of multiple myeloma Oncotarget 2019 10 24 2369 2383 10.18632/oncotarget.26792 31040928
7. Garfall AL Chimeric antigen receptor T cells against CD19 for multiple myeloma N Engl J Med 2015 373 11 1040 1047 10.1056/NEJMoa1504542 26352815
8. Mihara K T-cell immunotherapy with a？chimeric receptor against CD38 is effective in eliminating myeloma cells Leukemia 2012 26 2 365 367 10.1038/leu.2011.205 21836610
9. Ramos CA Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains J Clin Invest 2016 126 7 2588 2596 10.1172/JCI86000 27270177
10. Gogishvili T SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes Blood 2017 130 26 2838 2847 10.1182/blood-2017-04-778423 29089311
11. Smith EL Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector Mol Ther 2018 26 6 1447 1456 10.1016/j.ymthe.2018.03.016 29678657
12. Carrabba MG Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a？CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) Blood 2018 132 Supplement 1 5790 5790 10.1182/blood-2018-99-117974
13. Baumeister SH Phase I trial of Autologous CAR T cells targeting NKG2D Ligands in patients with AML/MDS and multiple myeloma Cancer Immunol Res 2019 7 1 100 112 10.1158/2326-6066.CIR-18-0307 30396908
14. Moreau P Chimeric antigen receptor T-cell therapy for multiple myeloma: a？consensus statement from The European Myeloma Network Haematologica 2019 104 12 2358 2360 10.3324/haematol.2019.224204 31439675
15. Li C Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T cell therapy in relapsed/refractory multiple myeloma Clin Lymphoma Myeloma Leuk 2019 19 10 e23 e24 10.1016/j.clml.2019.09.034
16. Gagelmann N B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis Eur J Haematol 2020 104 4 318 327 10.1111/ejh.13380 31883150
17. Lonial S Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Lancet 2016 387 10027 1551 1560 10.1016/S0140-6736(15)01120-4 26778538
18. Zhou X Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease Cancers 2020 10.3390/cancers12041035 33321907
19. Guo B CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma J Cell Immunother 2016 2 1 28 35 10.1016/j.jocit.2014.11.001
20. Garfall AL Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma JCI Insight 2018 10.1172/jci.insight.120505 29669947
21. Zhao WH A phase 1, open-label study of LCAR-B38M, a？chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma J Hematol Oncol 2018 11 1 141 10.1186/s13045-018-0681-6 30572922
22. Costello CL Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME) Blood 2019 134 Supplement_1 3184 3184 10.1182/blood-2019-129562
23. Wang M Identification and validation of predictive biomarkers to CD19- and BCMA-specific CAR T-cell responses in CAR T-cell precursors Blood 2019 134 Supplement_1 622 622 10.1182/blood-2019-122513
24. Popat R Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed/refractory multiple myeloma (RRMM) Blood 2019 134 Supplement_1 3112 3112 10.1182/blood-2019-126689
25. Li C A Bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a？phase 1 dose-climbing trial Blood 2019 134 Supplement_1 930 930 10.1182/blood-2019-130340
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.